Impact of hormonal therapy on NT-proBNP levels in breast cancer patients

Clicks: 1
ID: 323406
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #212 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background/Introduction Hormonal Therapy is a cornerstone in the management of hormone receptor-positive (HR+) breast cancer (BC)(1). While generally considered to have a favourable safety profile compared to chemotherapy or targeted therapies like trastuzumab, emerging evidence suggest that Aromatase Inhibitors (AI) maybe associated with an increased risk of Cardiovascular (CV) disease (2). Cardiac imaging parameters - left ventricular ejection fraction (LVEF) and left ventricular global longitudinal strain (LVGLS) – together with circulating biomarkers, including N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin, are routinely used for the detection of subclinical cancer therapy related cardiac dysfunction (CTRCD) (3). However, the potential cardiotoxic effects of hormonal therapy in patients with BC remain insufficiently investigated. Purpose The aim of this study was to assess the cardiotoxic effects of aromatase inhibitor therapy in patients with breast cancer. Methods We analyzed data of patients from the ongoing CARDIOCARE Prospective Clinical Study with histologically confirmed BC treated exclusively with adjuvant hormonal therapy (n=147). Baseline cardiovascular risk factors were descriptively analyzed (Table 1). Patients were classified into group A (those who developed CTRCD according to HFA-ICOS universal definition) and group B (those without CTRCD). For the present analysis, patients lacking paired NT-proBNP data were excluded, resulting in a final cohort of 25 patients with CTRCD and 38 patients without CTRCD. Statistical significance for NT-proBNP was assessed using a one-sample Wilcoxon signed-rank test (μ=0.5) on the normalized data. Results In the CTRCD group, median NT-proBNP increased significantly from 117.5 pg/mL at baseline to 212 pg/mL after 3 months of therapy (p < 0.001), and to 150.3 pg/mL after 12 months of therapy (p < 0.001). While LVEF, LVGLS and troponin levels did not change significantly. Conversely, in the non-CTRCD group, median NT-proBNP levels remained stable (Baseline: 104.8 pg/mL vs. 3 months: 106.8 pg/mL (p = 0.055) vs 6 months (101.4 pg/mL) vs 9 months (81.6 pg/mL) vs 12 months (98.7 pg/mL). Troponin and imaging biomarkers (LVEF, LVGLS) also remained stable across all four assessed time points (at 3, 6, 9 and 12 months from the initiation of AI) in this group (Table 2). Conclusion In this cohort of breast cancer patients treated exclusively with AI, a statistically significant increase in NT-proBNP levels was observed as early as 3 months and again at 12 months among those who developed CTRCD, despite preserved systolic function and deformation mechanics and troponin levels. Although limited by sample size, these findings suggest that AI therapy may be associated with early subclinical myocardial stress detectable by NT-proBNP elevation in patients who develop CTRCD, highlighting the potential value of biomarker-based surveillance in this population.Table1Descriptive statistics Table 2Longitudinal changes
Reference Key
openalex_W7172307373 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors E Charalambous, C Andreou, K Keramida, C Brown, P Vogazianos, D Vraxnos, M Kedariti, A Constantinidou, E Kampouroglou, A Papakonstantinou, C Cipolla, K Mazzocco, D Fotiadis, A Antoniades
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.096
URL
https://doi.org/10.1093/eurheartjsupp/suag097.096
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.